News – Page 861 – Endpoints News

SIGN UP

The first drug from Eli Lilly's new-look oncology group gets speedy review as Bilenker's team hones focus

6 years ago

Sanofi stops all but the most urgent trips to China; Flurry of orphan drug designations arrive

6 years ago

Novartis rethinks CML strategy for next-gen allosteric drug due for a pivotal readout later this year

6 years ago

What in the world is a MINOR CRL, Amphastar?

6 years ago

Patient dies in a troubled HBV drug program — forcing developers to scrap the drug and shift focus. To STING

6 years ago

Putting buybacks on hold, Pfizer’s CEO is plotting a string of important PhII deals in the year ahead. You’ve ...

6 years ago

How do American scientists get embroiled in China scandals? Moffitt investigation sheds some light

6 years ago

Laurence Reid returns as CEO of Decibel Therapeutics — as Steve Holtzman retires

6 years ago

Ionis/Akcea's Pfizer-partnered antisense drug shows promise in study, with implications for Arrowhead RNAi asset ...

6 years ago

Following a NASH crash, Conatus turns the keys over to regenerative med player

6 years ago

Top Harvard chemist caught up in FBI’s 'Thousand Talents' dragnet, accused of lying about Chinese connections, pay

6 years ago

Eyeing a trio of trial initiations, Jim Wilson's gene therapy startup woos Bruce Goldsmith from Deerfield as CEO

6 years ago

Flagship's first venture of 2020 is out, and it's all about sperm

6 years ago

Pfizer axes 6 early to late-stage cancer studies from the pipeline — with one other cut for sickle cell disease

6 years ago

Incyte scores much needed PhIII success — and of course it’s delivered by ruxolitinib

6 years ago

Sanofi/Regeneron Dupixent; Alkermes' antipsychotic get dates with the FDA; Concert wins reprieve in Incyte patent ...

6 years ago

Can we make the antibiotic market great again?

6 years ago

The FDA unveils a new regulatory framework to speed along gene therapies, rewarding the leading players

6 years ago

Mike Bloomberg joins a growing chorus of Democratic presidential candidates threatening to go after drug patents

6 years ago

Ex-Novartis CEO Joe Jimenez is taking another crack at opening a new chapter in his career — and that includes a ...

6 years ago

J&J's Spravato gets no love from NICE, jeopardizing its prospects in the UK

6 years ago

The FTC and New York state accuse Martin Shkreli of running a drug monopoly. They plan to squash it — and ...

6 years ago

Acceleron resurrects blockbuster hopes for sotatercept with positive PhII — and shares rocket up

6 years ago

Civica and Blue Cross Blue Shield launch new venture to lower generic prices

6 years ago

First page Previous page 858 859 860861862 863 864 Next page Last page